Palisade Bio, Inc. (PALI) Gains Health Canada CTA OK for Phase 2b UC Trial

Palisade Bio received Health Canada CTA clearance for ASCENTRA-UC, expanding its global Phase 2 trial of oral PALI-2108 in moderately to severely active ulcerative colitis. Primary 12-week induction results from ~204 patients are expected in H2 2027.Material DetailsContext by AI AnalystThis is an e…